PT1047449E - Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal - Google Patents

Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal

Info

Publication number
PT1047449E
PT1047449E PT98949847T PT98949847T PT1047449E PT 1047449 E PT1047449 E PT 1047449E PT 98949847 T PT98949847 T PT 98949847T PT 98949847 T PT98949847 T PT 98949847T PT 1047449 E PT1047449 E PT 1047449E
Authority
PT
Portugal
Prior art keywords
myelin
methods
transitoriamentally
nervoso
mamifero
Prior art date
Application number
PT98949847T
Other languages
English (en)
Inventor
Jason K Dyer
Hans S Keirstead
John Steeves
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2219683 external-priority patent/CA2219683A1/en
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of PT1047449E publication Critical patent/PT1047449E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT98949847T 1997-10-28 1998-10-28 Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal PT1047449E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2219683 CA2219683A1 (en) 1997-10-28 1997-10-28 Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
CA2251410 1998-10-16

Publications (1)

Publication Number Publication Date
PT1047449E true PT1047449E (pt) 2004-04-30

Family

ID=25679779

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98949847T PT1047449E (pt) 1997-10-28 1998-10-28 Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal

Country Status (11)

Country Link
US (2) US6969516B1 (pt)
EP (1) EP1047449B1 (pt)
JP (1) JP2001521008A (pt)
AT (1) ATE249241T1 (pt)
AU (1) AU748143B2 (pt)
DE (1) DE69818106T2 (pt)
DK (1) DK1047449T3 (pt)
ES (1) ES2210829T3 (pt)
IL (2) IL135799A0 (pt)
PT (1) PT1047449E (pt)
WO (1) WO1999021581A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4095900A (en) * 1999-04-28 2000-11-10 University Of British Columbia, The Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
CN106220739A (zh) * 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
IL293603B2 (en) 2014-04-07 2024-03-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
RU2021121771A (ru) 2015-04-08 2022-01-12 Новартис Аг Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002003A1 (en) * 1989-08-04 1991-02-21 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US6020140A (en) * 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
DK0659083T3 (da) * 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies

Also Published As

Publication number Publication date
ATE249241T1 (de) 2003-09-15
IL135799A0 (en) 2001-05-20
AU9617998A (en) 1999-05-17
US6548061B1 (en) 2003-04-15
EP1047449B1 (en) 2003-09-10
WO1999021581A1 (en) 1999-05-06
JP2001521008A (ja) 2001-11-06
EP1047449A1 (en) 2000-11-02
ES2210829T3 (es) 2004-07-01
DK1047449T3 (da) 2004-01-26
US6969516B1 (en) 2005-11-29
AU748143B2 (en) 2002-05-30
IL135799A (en) 2011-01-31
DE69818106T2 (de) 2004-06-17
DE69818106D1 (de) 2003-10-16

Similar Documents

Publication Publication Date Title
Michaeli et al. The incidence and antigenic specificity of antibodies against denatured human collagen in rheumatoid arthritis
Osterland et al. Anti‐γ‐globulin factors in human sera revealed by enzymatic splitting of anti‐Rh antibodies
Clem et al. Phylogeny of immunoglobulin structure and function: II. Immunoglobulins of the nurse shark
PT1047449E (pt) Composicoes imunologicas e metodos de utilizacao para alterar transitoriamente a mielina do sistema nervoso central mamifero para promover a regeneracao neuronal
AR001811A1 (es) Anticuerpos anti-icam-1 modificados y su uso en eltratamiento de inflamaciones
ATE47155T1 (de) Monoklonaler antikoerper.
DE69309472D1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE439860T1 (de) Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikírpern
DE69014474D1 (de) Antikörper gegen TNF-Bindungsprotein I und deren F(ab)-Fragmente.
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
AR043826A1 (es) Formulaciones de proteinas y anticuerpos de alta concentracion
AR035786A2 (es) Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen
PT743856E (pt) Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE68925593D1 (de) Antikörper-Heterokonjugate zur Regulation der Lymphozytenaktivität
KR870005648A (ko) 슈도모나스 이루지노사 항원형에 대한 교차면역 반응성 및 교차보호성 단일분지계 항체
DE69021953T2 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
AR018020A1 (es) Procedimiento perfeccionado para estabilizar proteinas particularmente anticuerpos, su almacenamiento y reconstitucion
NO892125L (no) Kombinasjon av angiotensin-omvandlende-enzymhemmere med kaliumkanal-modulatorer samt deres anvendelse i legemidler.
CA2253078A1 (en) Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
BR9101117A (pt) Produto que compreende um ou mais veiculos de material enzimatico e processo para distribuir um agente ativo a um sitio
AR016681A1 (es) Deplecion de celulas th2; composiciones; metodos
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
Stolinsky et al. ON THE UNIVALENT FRAGMENTS OF HUMAN 7 S GAMMA-GLOBULIN.